All articles by Lopamudra Roy
Teva to sell assets in global women’s health business for $1.38bn
Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for $1.38bn.
Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases
Immunocore has secured up to $40m in investment from Bill & Melinda Gates Foundation to boost the development of soluble T-cell receptor (TCR)-based therapeutics to treat infectious diseases, in particular tuberculosis (TB) and human immunodeficiency virus (HIV).
NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells
A new study conducted by researchers from the National University of Singapore (NUS) has revealed that the co-treatment using artemisinin and aminolaevulinic acid (ALA) can potentially kill cancer cells and suppress tumour growth with fewer side effects.
GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing authorisation of Trelegy Ellipta as a maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs
Bristol-Myers Squibb has entered a global collaboration and licence agreement to use Halozyme Therapeutics’ Enhanze drug-delivery technology for the development of its subcutaneously administered immuno-oncology treatments.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Evotec and MaRS Innovation launch new drug-discovery partnership
German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario, Canada.
Fujifilm opens new cell culture process development laboratories in UK
Fujifilm Diosynth Biotechnologies has opened new and advanced 10,000ft² cell culture process development laboratories in Wilton Centre, Teesside, UK.
Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment
Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer.
US FDA advisory committee votes for GSK’s Shingrix to prevent shingles
The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s (GSK) Shingrix (HZ/su) to prevent herpes zoster (shingles) in adults of 50 years of age and above.
Janssen to stop further development of JNJ-4178 hepatitis C treatment
Janssen Sciences Ireland has taken a strategic decision to discontinue further development of its investigational regimen JNJ-4178 for the treatment of patients with hepatitis C.